Compare INKT & SCOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INKT | SCOR |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.4M | 101.6M |
| IPO Year | 2021 | 2007 |
| Metric | INKT | SCOR |
|---|---|---|
| Price | $11.97 | $4.99 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 11.9K | ★ 42.4K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 127.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,549,000.00 |
| Revenue This Year | N/A | $2.75 |
| Revenue Next Year | N/A | $7.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $8.48 | $4.60 |
| 52 Week High | $16.80 | $10.18 |
| Indicator | INKT | SCOR |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 42.11 |
| Support Level | $10.79 | $4.60 |
| Resistance Level | $12.04 | $7.72 |
| Average True Range (ATR) | 0.52 | 0.37 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 31.55 | 43.84 |
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.